Abstract
The ability of a quadrivalent human papilloma virus (HPV)-16/18/6/11 virus-like particles vaccine (Gardasil) to elicit HPV-specific cell-mediated immune responses was evaluated in antiretroviral therapy (ART)-treated HIV-infected young adults. Results showed that, after three doses of vaccine, central memory and effector memory CD4(+) and CD8(+) T lymphocytes, as well as HPV-specific interleukin (IL)2(+)/CD4(+), interferon-gamma (IFN-γ(+))/CD4(+), IFN-γ(+)/CD8(+) and tumour necrosis factor-alpha (TNF-α)(+)/CD8(+) T lymphocytes and Perforin and Granzyme B secreting CD8(+) T lymphocytes were significantly increased. Notably, results obtained in HIV-infected patients were comparable to those seen in HIV-uninfected age-matched healthy controls.
Publication types
-
Clinical Study
-
Observational Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Cytokines / metabolism
-
HIV Infections / complications
-
HIV Infections / immunology*
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage*
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology*
-
Human papillomavirus 16
-
Humans
-
Immunity, Cellular / drug effects*
-
Longitudinal Studies
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / prevention & control*
-
Prospective Studies
-
T-Lymphocyte Subsets / immunology*
-
Vaccination / methods*
-
Young Adult
Substances
-
Cytokines
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18